Abstract
ABSTRACTTo evaluate the cost effectiveness of six disease modifying anti-rheumatic drug (DMARD) treat-to-target treatment strategies for patients with rheumatoid arthritis in Zanzibar.A Markov model was used to calculate the cost-effectiveness of various DMARD strategies in the treatment of rheumatoid arthritis over a three-year period. A health-provider perspective was used and only outpatient costs were considered. The Clinical Disease Activity Index (CDAI) was utilized for measurement of efficacy and values were obtained from literature. Quality Adjusted Life Years (QALYs) were obtained from 122 patients attending the rheumatology clinic at Mnazi Mmoja Hospital. Data on costs were obtained from the central medical stores and hospital administration. Treatment strategies were given in sequential approach based on treat to target goals of therapy. This included methotrexate monotherapy, methotrexate + sulfasalazine + hydroxychloroquine, methotrexate followed by one or two biologic/targeted-synthetic DMARDs (b/tsDMARDs). Probabilistic and one way sensitivity analysis were performed. Scenario analysis was undertaken comparing drug prices from India and Scandinavia.Costs of therapy/patient/three years ranged from USD 634 for methotrexate monotherapy and USD 5011 for methotrexate and two consecutive b/tsDMARDs. The highest and lowest effects were 2.209 and 2.079 QALYs gained from methotrexate therapy + two consecutive b/tsDMARDs and methotrexate monotherapy, respectively. From a healthcare perspective methotrexate monotherapy was the cost-effective option at a willingness to pay of USD 282. Pairwise comparison also favored methotrexate monotherapy as the feasible option. We found that increasing the willingness to pay led to a change in the most acceptable option from methotrexate monotherapy to methotrexate followed by b/tsDMARD.Methotrexate monotherapy is the cost-effective option for the management of rheumatoid arthritis in Zanzibar. Other options may be feasible if the willingness to pay threshold is increased or the drug prices are lowered, particularly for the b/tsDMARDs.
Publisher
Cold Spring Harbor Laboratory
Reference65 articles.
1. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review;Rheumatol Int,2021
2. Rudan I , Sidhu S , Papana A , Meng S , Xin–Wei Y , Wang W , et al. Prevalence of rheumatoid arthritis in low– and middle–income countries: A systematic review and analysis. J Glob Health. 2015 Jun 1;5.
3. The outlook of rheumatological care in Africa: Current state, challenges, and recommendation
4. Co-morbidities in established rheumatoid arthritis;Best Pract Res Clin Rheumatol [Internet],2011
5. Global Burden of Rheumatoid Arthritis and Associations with Sex, Sociodemographic Status, Geographic Regions, and Risk Factors 1990-2019: A Systematic Analysis of the Global Burden of Disease Study 2019